Affiliated Zhongshan Hospital of Dalian University
14
4
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
29%
4 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Assessment of Dialysis Initiation by a Fuzzy Mathematics Equation
Role: collaborator
China Cognition and Aging Study
Role: collaborator
The Chinese Familial Alzheimer's Network
Role: collaborator
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
Role: collaborator
Genotype-guided Treatment in DLBCL
Role: collaborator
Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
Role: collaborator
CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma
Role: collaborator
Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China
Role: collaborator
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Role: collaborator
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
Role: collaborator
A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC
Role: collaborator
Radiomics Multifactorial Biomarker for Pulmonary Nodules
Role: collaborator
A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC
Role: collaborator
TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
Role: collaborator
All 14 trials loaded